Based on the Janux Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Janux Therapeutics Inc is USD 70.86 over the next 12 months. Janux Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Janux Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Janux Therapeutics Inc’s stock price was USD 48.76. Janux Therapeutics Inc’s stock price has changed by -9.57% over the past week, -2.11% over the past month and +461.75% over the last year.
No recent analyst target price found for Janux Therapeutics Inc
No recent average analyst rating found for Janux Therapeutics Inc
Company Overview Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Read Less
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical cand...Read More
Frequently Asked Questions About Janux Therapeutics Inc (JANX) Stock
Based on ratings from 5 analysts Janux Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on JANX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for JANX is USD 70.86 over the next 12 months. The maximum analyst target price is USD 100 while the minimum anlayst target price is USD 42.
Unfortunately we do not have enough data on JANX's stock to indicate if its overvalued.
The last closing price of JANX's stock was USD 48.76.
The most recent market capitalization for JANX is USD 2.84B.
Based on targets from 5 analysts, the average taret price for JANX is projected at USD 70.86 over the next 12 months.
This means that JANX's stock price may go up by +45.32% over the next 12 months.
We can't find any ETFs which contains Janux Therapeutics Inc's stock.
As per our most recent records Janux Therapeutics Inc has 69 Employees.
Janux Therapeutics Inc's registered address is 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130.
You can get more information about it from Janux Therapeutics Inc's website at https://www.januxrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Janux Therapeutics Inc (JANX) Stock
Based on ratings from 5 analysts Janux Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on JANX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for JANX is USD 70.86 over the next 12 months. The maximum analyst target price is USD 100 while the minimum anlayst target price is USD 42.
Unfortunately we do not have enough data on JANX's stock to indicate if its overvalued.
The last closing price of JANX's stock was USD 48.76.
The most recent market capitalization for JANX is USD 2.84B.
Based on targets from 5 analysts, the average taret price for JANX is projected at USD 70.86 over the next 12 months.
This means that JANX's stock price may go up by +45.32% over the next 12 months.
We can't find any ETFs which contains Janux Therapeutics Inc's stock.
As per our most recent records Janux Therapeutics Inc has 69 Employees.
Janux Therapeutics Inc's registered address is 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130.
You can get more information about it from Janux Therapeutics Inc's website at https://www.januxrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for JANX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
